Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 495 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: HYDROCORTISONE Clear all
Not listed No phase listed Observational

Study of the Approximate Entropy of Adrenocorticotropic Hormone and Cortisol Secretion in Patients With Head Injury

NCT00006270
View directory record Official record
Conditions
Brain Injury, Craniocerebral Trauma
Interventions
cosyntropin, metyrapone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
20 Years to 35 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome

NCT00936741
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
mifepristone
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Birmingham, Alabama • Escondido, California • Stanford, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 22, 2026, 2:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

WHNRC (Western Human Nutrition Research Center) Honey Study

NCT06107231
View directory record Official record
Conditions
Postprandial Glycemia, Metabolic Stress, Cognitive Change, Satisfaction, Personal
Interventions
Honey, Sucrose, Honey plus almonds, Sucrose plus almonds
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 40 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Effect of Immediate Implant Placement and Provisionalization in the Esthetic Zone

NCT02021331
View directory record Official record
Conditions
Jaw, Edentulous, Partially
Interventions
immediate implant placement without provisionalization, immediate implant placement with immediate provisionalization
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 79 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional

Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream

NCT02153762
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Locoid Lipocream, Hylatopic Plus
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
3 Months and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Onnit Labs New Mood Supplementation in Healthy College Students

NCT05109923
View directory record Official record
Conditions
Mental Health Wellness 1
Interventions
Multi-Ingredient Herbal Supplement, Placebo Supplement
Dietary Supplement
Lead sponsor
University of Idaho
Other
Eligibility
18 Years to 24 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Moscow, Idaho
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population

NCT01137032
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis
Interventions
Pandel Cream 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
3 Months and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
3
States / cities
Omaha, Nebraska • Hilton Head Island, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome

NCT05307328
View directory record Official record
Conditions
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion, Cortisol Overproduction, Ectopic ACTH Secretion
Interventions
SPI-62, Placebo
Drug
Lead sponsor
Sparrow Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
8
States / cities
Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Brain Connections and Blood Pressure

NCT03736434
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Mindfulness and DASH Diet Education, Education group
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
65 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 1 Interventional Results available

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

NCT03792256
View directory record Official record
Conditions
Leukemia, Lymphocytic, Lymphoblastic Lymphoma, T-cell Lymphoma, T-cell Leukemia, Recurrent Disease, Acute Leukemia
Interventions
Palbociclib, Cytarabine, Methotrexate, Hydrocortisone, Doxorubicin, Prednisolone, Vincristine, Pegaspargase, Prednisone
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 31 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Birmingham, Alabama • Loma Linda, California • Orange, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Early Phase 1 Interventional

Stress Management Toolkit for People Living With Dementia and Their Care Partners

NCT05465551
View directory record Official record
Conditions
Dementia, Stress, Caregiver Burden
Interventions
Stress Management Toolkit
Combination Product
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 22, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Age-Related Changes in Stress Hormone Regulation

NCT00018369
View directory record Official record
Conditions
Physiological Processes, Aging
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2004
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 22, 2026, 2:38 PM EDT
Completed No phase listed Observational

Novel Real-world Methods in Social Drinkers and AUD

NCT05155176
View directory record Official record
Conditions
Alcohol Drinking, Alcohol Abuse, Alcohol Use Disorder
Interventions
Intensive Day Monitoring
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Phase 2 Interventional

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

NCT06390319
View directory record Official record
Conditions
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
Interventions
Dexamethasone, Vincristine, Daunorubicin, Calaspargase pegol, Dasatinib, Venetoclax, Bortezomib, Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine), Cyclophosphamide, Cytarabine, Mercaptopurine, Nelarabine, Methotrexate, Thioguanine
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
San Diego, California • Charlotte, North Carolina • Tulsa, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Recruiting Phase 1 Interventional

Venetoclax Basket Trial for High Risk Hematologic Malignancies

NCT05292664
View directory record Official record
Conditions
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary, Myelodysplastic Syndromes, Previously Treated, Treatment-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Lymphoblastic Lymphoma, in Relapse, Lymphoblastic Lymphoma, Refractory, Acute Leukemia of Ambiguous Lineage in Relapse, Acute Leukemia of Ambiguous Lineage
Interventions
Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone, Leucovorin, Dexamethasone, Vincristine, Doxorubicin, Dexrazoxane, Calaspargase Pegol, Erwinia asparaginase
Drug
Lead sponsor
Andrew E. Place, MD
Other
Eligibility
1 Year to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression

NCT02837432
View directory record Official record
Conditions
Depression
Interventions
Hydrocortisone acetate, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional

Neuroendocrine Mechanisms in Behavioral Treatment of Insomnia

NCT00303342
View directory record Official record
Conditions
Insomnia
Interventions
mind body treatment, desensitization
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 22, 2026, 2:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Stress Hormones and IUDs

NCT03499379
View directory record Official record
Conditions
Contraception, Mood Change
Interventions
Mirena, Paraguard
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Not applicable Interventional Results available

Building Resiliency Among Caregivers of Curvivors and Metavivors

NCT05702723
View directory record Official record
Conditions
Stress, Cancer Diagnosis, Distress, Emotional
Interventions
Smart-3RP, Enhanced Usual Care
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD

NCT00186628
View directory record Official record
Conditions
Leukemia, Mast-Cell, Mantle-cell Lymphoma
Interventions
Total lymphoid irradiation, Rituximab, Anti-thymoglobulin, rabbit (ATG, rabbit ATG), Cyclosporine, Mycophenylate mofetil, Filgrastim, Granisetron, Solumedrol, Acetaminophen, Diphenhydramine, Hydrocortisone
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 76 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Oct 22, 2026, 2:38 PM EDT
Completed Phase 4 Interventional Results available

Study of Alemtuzumab Versus Anti-thymocyte Globulin to Help Prevent Rejection in Kidney and Pancreas Transplantation

NCT00331162
View directory record Official record
Conditions
Graft Rejection
Interventions
Alemtuzumab, Anti-Thymocyte Globulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 65 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 22, 2026, 2:38 PM EDT